ORs (95% credible interval) according to network meta-analyses for the survival for all pairwise comparisons in randomised controlled trials
| <3 cm for 1-year survival | ||||
| PEI | ||||
| 1.17 (0.11 to 4.66) | TR | |||
| 0.08 (0 to 0.38) | 0.15 (0 to 0.80) | MWA | ||
| 0.67 (0.28 to 1.35) | 1.25 (0.16 to 4.64) | 173.30 (1.90 to 537.40) | RFA | |
| 0.64 (0.18 to 1.61) | 1.08 (0.15 to 3.78) | 152.70 (1.44 to 505.80) | 0.97 (0.42 to 1.98) | RES |
| <3 cm for 3-year survival | ||||
| PEI | ||||
| 1.02 (0.14 to 3.56) | TR | |||
| NA | NA | MWA | ||
| 0.79 (0.45 to 1.39) | 1.54 (0.25 to 13.43) | NA | RFA | |
| 0.58 (0.29 to 1.16) | 1.17 (0.16 to 4.17) | NA | 0.75 (0.41 to 1.31) | RES |
| <3 cm for 5-year survival | ||||
| PEI | ||||
| 3.93 (0.03 to 19.61) | TR | |||
| NA | NA | MWA | ||
| 0.94 (0.08 to 3.97) | 2.87 (0.04 to 13.43) | NA | RFA | |
| 0.50 (0.04 to 2.04) | 0.84 (0.03 to 4.18) | NA | 0.72 (0.10 to 2.47) | RES |
| 3 to 5 cm for 1-year survival | ||||
| PEI | ||||
| NA | TR | |||
| NA | NA | MWA | ||
| NA | 3.40 (0.64 to 11.93) | NA | RFA | |
| NA | 1.00 (0 to 5.00) | NA | 0.25 (0 to 1.47) | RES |
| 3 to 5 cm for 3-year survival | ||||
| PEI | ||||
| NA | TR | |||
| NA | NA | MWA | ||
| NA | 3.98 (0.71 to 15.22) | NA | RFA | |
| NA | 1.14 (0 to 6.20) | NA | 0.24 (0 to 1.25) | RES |
| 3 to 5 cm for 5-year survival | ||||
| PEI | ||||
| NA | TR | |||
| NA | NA | MWA | ||
| NA | 7.64 (0.14 to 42.49) | NA | RFA | |
| NA | 12.87 (0.02 to 44.43) | NA | 1.05 (0.03 to 5.33) | RES |
| ≤5 cm for 1-year survival | ||||
| PEI | ||||
| 0.29 (0.09 to 0.73) | TR | |||
| 0.27 (0.05 to 0.84) | 1.09 (0.16 to 3.50) | MWA | ||
| 0.65 (0.33 to 1.13) | 2.69 (1.02 to 6.04) | 3.84 (0.81 to 11.60) | RFA | |
| 0.37 (0.13 to 0.82) | 1.50 (0.48 to 3.67) | 2.01 (0.47 to 5.70) | 0.57 (0.27 to 1.08) | RES |
| ≤5 cm for 3-year survival | ||||
| PEI | ||||
| 0.64 (0.19 to 1.67) | TR | |||
| 1.05 (0.12 to 4.56) | 1.86 (0.21 to 7.59) | MWA | ||
| 0.86 (0.39 to 1.79) | 1.56 (0.66 to 3.25) | 1.77 (0.22 to 6.24) | RFA | |
| 0.55 (0.19 to 1.44) | 0.98 (0.35 to 2.41) | 1.00 (0.16 to 3.30) | 0.65 (0.31 to 1.29) | RES |
| ≤5 cm for 5-year survival | ||||
| PEI | ||||
| 0.53 (0.06 to 1.90) | TR | |||
| NA | NA | MWA | ||
| 0.74 (0.16 to 2.00) | 2.29 (0.41 to 7.61) | NA | RFA | |
| 0.41 (0.11 to 1.02) | 1.35 (0.23 to 4.69) | NA | 0.66 (0.20 to 1.62) | RES |
The reference treatment (1.00) for all comparisons is listed to the right hand side.
MWA, microwave ablation; PEI, percutaneous ethanol injection; RES, resection; RFA, radiofrequency ablation; TR, transcatheter arterial chemoembolisation and radiofrequency ablation.